Navigation Links
Collaborating with Patient Advocacy Groups to Educate Physicians, Patients and Thought Leaders
Date:6/13/2010

CHAPEL HILL, N.C., June 11 /PRNewswire/ -- In the biopharma sector, collaborating with patient advocacy groups is a critical part of educating patients and physicians. Patient advocacy groups are a trusted resource for consumers as they seek out information on new therapies, especially novel therapies. Using an online research survey and deep-dive interviews with selected participants, Best Practices, LLC conducted a research project to identify winning practices in patient advocacy group collaboration and relationship management.

"Collaborating with Patient Advocacy Groups to Educate the Marketplace" is a 125-page report that identifies successful tactics and strategies for working with patient advocacy groups and managing relationships. 

This benchmarking study identifies valuable practices in starting and maintaining collaborative relationships with patient advocacy groups. The research also examines ideal structures and skill sets for pharma groups that deal with advocacy groups. In addition, the study shares emerging trends and challenges in patient advocacy.

Fifty-eight advocacy leaders from 43 companies such as Abbott, Wyeth, Genentech, Novartis, Bayer, Amgen, Astellas, Takeda, Bristol-Myers Squibb and J&J shared their practices and insights into advocacy group collaborations. More than a dozen organizations participated in deep-dive interviews to provide actionable insights into working with the advocacy world.

Key topics of this report include:

  • Understanding the Advocacy Landscape
  • Managing Advocacy Relationships
  • Managing Relationships with Hostile Groups
  • Structuring High Performance Biopharma Advocacy Groups
  • Using New Technologies
  • Current Trends and Future Directions

Executives, directors and managers at device, pharmaceutical and biotech organizations who work in patient advocacy functions can use this research to compare their group's approaches and tactics for advocacy group interactions with those of leading organizations.

To learn more about this research project, download a complimentary report summary at: http://www3.best-in-class.com/rr1006.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for 17 years; our clients include 48 out of the top 50 pharmaceutical companies. For more information visit: http://www3.best-in-class.com.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
2. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. Over 205 Inches Lost by Chicago Area Patients at Complete Clinics Using Zerona(TM) Lipo Laser
5. FIRMAGON® Results in Fast, Long-Term Suppression of Testosterone in Prostate Cancer Patients Without Initial Testosterone Surge
6. Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year
7. Reportlinker Adds China Patient Monitoring Market Outlook to 2016
8. Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian
9. Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder
10. California Patient Recruiter Sentenced to 12 Months in Prison for Medicare Fraud in Power Wheelchair Scam
11. New Montefiore Program Helps Patients Avoid Potentially Life-Threatening Medication Errors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):